Industry

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment

Biofarma Group announces the acquisition of Nutraskills

The Italian-based leader in the European nutraceutical CDMO market announces the acquisition of Nutraskills, a French company specialized in the research and development, production, and packaging of food supplements for…

Lallemand Health Solutions gains new Canadian claims showing its probiotics can help formula-fed babies develop a similar microflora as to breast-fed ones

The intestinal microflora of infants should contain a high proportion of Bifidobacteria during their first year of life to be well preserved and balanced

Universal DX: Microbiome Signatures in Plasma Can Help Detect Early-Stage Colorectal Cancer

Company Presents Data at ESMO Congress Showing Link Between Gut Bacteria and Early Colorectal Cancer Detection

Lesaffre Acquires Recombia Biosciences and Entry into the World of Synthetic Biology

The acquisition is the culmination of a strategic partnership initiated in 2020 to accelerate the development of yeasts for sustainable production of fermented ingredients.

How Bayer Consumer Healthcare is Involved in Microbiome Research

Holger Lenz discusses the interest of Bayer in the microbiome space during Microbiome Connect: Europe 2022.

Digbi Health and Novo Nordisk pilot testing Genetic and Gut Microbiome-based Digital Solutions for Prevention of Obesity

Digbi Health is enrolled in Novo Nordisk's Global Prevention Accelerator Program for the prevention of obesity and related cardiometabolic conditions.

Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding Company as AcuraBio

AcuraBio is a globally focussed organization bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries.

Metabolon and University of Oxford Enter Partnership to Identify Biomarkers related to Parkinson’s disease

Metabolon and the Oxford Parkinson's Disease Centre will identify new metabolomic biomarkers to advance Parkinson's research and detect new therapeutic targets

Inactivated microbes could pave the way to next generation probiotics approval

Simone Guglielmetti (University of Milan) discusses the use of inactivated microbes as alternative to live probiotics.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top